TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06258629

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry on bone marrow aspiration
Description: Flowcytometry on bone marrow aspiration

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry on bone marrow aspiration
Description: Flowcytometry on bone marrow aspiration

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry on bone marrow aspiration
Description: Flowcytometry on bone marrow aspiration
Study: NCT05183581

Intervention type: DEVICE
Group type: OTHER
Intervention: Feeling Hot sensor system
Description: The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
Study: NCT06189001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin 0.2 IU/min during experimental days
Study: NCT03970031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet
Study: NCT05516589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260mg/m\^2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg PO QD
Study: NCT03268837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Bolus
Description: The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
Study: NCT05913167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic nephrectomy
Description: laparoscopic nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic nephrectomy
Description: laparoscopic nephrectomy
Study: NCT04642430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Refer to Apixaban group
Study: NCT06189001

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (saline)
Description: Intravenous saline during experimental days
Study: NCT04642430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Refer to Rivaroxaban group
Study: NCT04788615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 20mg Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First line DMT
Description: any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
Study: NCT06162728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: Subcutaneous Administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03268837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
Study: NCT06540495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salaso Virtual Exercise Program
Description: Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
Study: NCT06009029

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation(SBRT)
Description: SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (GLS-010)
Description: Zimberelimab (GLS-010),240mg d1 iv Q21D
Study: NCT06467942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine and Lactobacillus
Description: combined drug group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine
Description: Single Chinese medicine group
Study: NCT05242458

Intervention type: DRUG
Intervention: Ustekinumab
Description: No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
Study: NCT06590610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial pressure wave (RPW) - Intelect RPW2 Chattanooga
Description: RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
Study: NCT05298033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2 % Topical Ointment
Description: Twice daily crisaborole 2% topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2 % Topical Ointment
Description: Twice daily crisaborole 2% topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 0.01% topical ointment
Description: Twice daily PF-07038124 0.01% topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 0.01% topical ointment
Description: Twice daily PF-07038124 0.01% topical ointment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBUVB phototherapy
Description: Home narrow band UVB phototherapy exposure sessions 3 times per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBUVB phototherapy
Description: Home narrow band UVB phototherapy exposure sessions 3 times per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBUVB phototherapy
Description: Home narrow band UVB phototherapy exposure sessions 3 times per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham phototherapy
Description: Non-NBUVB visible light radiation exposure sessions 3 times per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham phototherapy
Description: Non-NBUVB visible light radiation exposure sessions 3 times per week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham phototherapy
Description: Non-NBUVB visible light radiation exposure sessions 3 times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Twice daily vehicle ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Twice daily vehicle ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Twice daily vehicle ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Twice daily vehicle ointment
Study: NCT06587516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Warmup Program
Description: This intervention consists of a structured warm-up routine specifically designed to enhance neuromuscular function and balance. The program includes exercises such as two way forward lunge, single-leg balance, multidirectional lunges, single-leg hops forward and backward, and single-leg calf raises. Each exercise is aimed at improving proprioception, dynamic stability, and lower limb strength.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Warmup Program
Description: This intervention involves a conventional warm-up program. It includes general stretching exercises and light jogging intended to prepare the body for physical activity.
Study: NCT06114953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine
Description: Mizoribine+glucocorticoid+tacrolimus after kidney transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
Study: NCT06586541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in attending team rounds
Description: Family members can participate both in-person and virtually, which can vary daily if desired. If the family member wishes to participate in-person, they will be invited to be present when the team rounds in the ICU. If the family member wishes to participate virtually, they will be provided with a personalized link by email to attend rounds.
Study: NCT06587139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Connection Project (TCP)
Description: The Teen Connection Project (TCP) includes seven 90-minute sessions facilitated by transgender and/or gender minority (TGM) adults. Each transgender and/or gender minority youth (TGMY) will be paired with a TGM adult mentor based on TGMYs' rank-ordered preference for mentors. The research team seeks to match mentors \& mentees such that each TGMY is matched with one of their top 3 preferred mentors. Mentors and mentees participate together in each session along with other mentors \& mentees. Facilitators direct activities/discussion to promote TGMY social-emotional skills acquisition and facilitate mentor-mentee conversations. TCP sessions also include mentor-mentee breakout sessions where mentors share challenges they personally faced as TGMY and how they overcame them. Break-out discussions focus on self-acceptance, coming out, dating questions, hopes and goals for the future, \& how other marginalized social identities, such as race and ethnicity, intersect with identifying as TGMY.
Study: NCT06467942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus
Description: Single Lactobacillus group
Study: NCT06020079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation
Study: NCT04109118

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
Description: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).

Intervention type: DRUG
Group type: OTHER
Intervention: BZD discontinuation protocol
Description: All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
Study: NCT05183763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-MAP health coaching
Description: Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
Study: NCT05556356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: pre-operative acetaminophen (1000mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Multivitamin
Description: pre-operative Multivitamin
Study: NCT05183763

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication reminder tools
Description: Medication-taking reminder app and pillbox

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication reminder tools
Description: Medication-taking reminder app and pillbox
Study: NCT06637514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517: 75 mg BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet: BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517: 150 mg BID
Study: NCT04821856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil and flavoring solution, also manufactured by THC Pharma
Study: NCT05734989

Intervention type: DIAGNOSTIC_TEST
Intervention: BP
Description: Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: HbA1c will screen to identify patients with Type 2 diabetes

Intervention type: BEHAVIORAL
Intervention: PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Description: Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
Study: NCT00535457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Magic Tricks
Description: Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction.
Study: NCT06637410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
Study: NCT06402630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STS01
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study: NCT06637410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
Study: NCT06639841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Psychotherapy
Description: Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness.
Study: NCT03553615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: oral anti-parasitic agent taken as a weekly dose for four weeks
Study: NCT06055075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
Study: NCT06402630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STS01
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STS01
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study: NCT06642493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion.